Respiratory Virus Panels in Dogs and Cats: A Comprehensive Review

Introduction

Respiratory diseases are among the most common presenting complaints in canine and feline clinical practice. These conditions are frequently caused by viral and bacterial pathogens, often acting synergistically in complex polymicrobial infections [1, 2]. The accurate identification of the etiologic agent or agents involved is critical for appropriate therapeutic decision-making, prognostication, and infection control [3, 4]. Traditional diagnostic methods, including viral isolation and serology, have largely been supplanted by molecular techniques, principally polymerase chain reaction (PCR)-based panels that enable rapid, sensitive, and multiplexed detection of multiple pathogens simultaneously [5, 6]. This article provides an exhaustive review of respiratory virus panels in dogs and cats, focusing on the virologic targets, assay design principles, clinical interpretation, and the integration of molecular diagnostics into veterinary practice.

Pathogens Included in Canine Respiratory Panels

The canine infectious respiratory disease complex (CIRDC) encompasses a group of viral and bacterial pathogens that cause clinical signs ranging from mild tracheobronchitis to severe pneumonia [2, 7]. Contemporary multiplex PCR panels for canine respiratory disease typically include the following viral targets: canine parainfluenza virus (CPIV), canine adenovirus type 2 (CAV-2), canine distemper virus (CDV), canine respiratory coronavirus (CRCoV), influenza A virus (canine influenza virus, CIV), and occasionally canine herpesvirus type 1 (CHV-1) [5, 4, 8]. Bacterial targets commonly include Bordetella bronchiseptica, Streptococcus equi subsp. zooepidemicus, Mycoplasma cynos, and Mycoplasma canis [1, 4, 8].

A retrospective analysis of canine respiratory PCR panels submitted to a major diagnostic laboratory revealed that B. bronchiseptica and M. cynos were among the most frequently detected agents, followed by CPIV and CRCoV [1]. Co-infections involving two or more pathogens are common, reflecting the polymicrobial nature of CIRDC [1, 2]. A longitudinal study during the winter 2023-2024 season demonstrated that using multiplex qPCR/RT-qPCR assays combined with next-generation sequencing (NGS) allowed detection of unexpected or novel viral sequences, including taupapillomaviruses, in dogs with respiratory signs [5, 9]. This highlights the value of comprehensive viral discovery in understanding the etiology of respiratory disease.

Pathogens Included in Feline Respiratory Panels

Feline upper respiratory tract disease (FURTD) is similarly complex, with viral pathogens playing a dominant role. Feline herpesvirus type 1 (FHV-1) and feline calicivirus (FCV) are the primary viral agents, together accounting for a large proportion of cases [10]. Additional viral targets sometimes included in panels are feline reovirus and influenza A virus, though the latter is less common in cats [3]. Bacterial agents commonly incorporated include Bordetella bronchiseptica, Chlamydia felis, and Mycoplasma felis [3, 10].

A study examining the frequency of respiratory pathogens in early 2020 found that M. felis and B. bronchiseptica were frequently detected in samples submitted from both dogs and cats [3]. Importantly, this study also screened for SARS-CoV-2, which was detected at low frequency in both species, demonstrating the utility of respiratory panels for emerging zoonotic and reverse-zoonotic pathogens [3, 6]. The chronic clinical signs of upper respiratory tract disease in cats have been associated not only with specific pathogens but also with alterations in the composition of the gut and respiratory microbiomes, suggesting that host-microbiome interactions modulate disease expression [10].

Assay Design and Technical Considerations

Respiratory virus panels are most commonly designed as multiplex real-time PCR (qPCR) or reverse-transcription real-time PCR (RT-qPCR) assays [4, 6, 8]. These methods employ target-specific primers and fluorescent hydrolysis probes (e.g., TaqMan) to achieve simultaneous detection of DNA and RNA viruses in a single reaction [6, 11]. The development of a one-step four-plex qPCR/RT-qPCR assay for simultaneous detection of SARS-CoV-2 and other CIRDC pathogens demonstrates the feasibility of combining multiple targets without sacrificing analytical sensitivity [6]. Similarly, a three-panel multiplex assay has been designed to detect nine canine respiratory pathogens, with each panel containing three targets resolved by distinct fluorophores [8].

The analytical performance of these assays is characterized by limit of detection, analytical specificity, and efficiency. Validation studies report limits of detection in the range of 10 to 100 genome copies per reaction for most targets [4, 8]. Cross-reactivity with non-target organisms is minimized through careful primer and probe design, in silico specificity analysis, and empirical testing against a panel of related and unrelated pathogens [4]. Internal positive controls, typically an exogenous RNA or DNA spike, are included to monitor extraction efficiency and the presence of PCR inhibitors [8, 11].

The use of nanoscale PCR technology, including microfluidic platforms, has enabled high-throughput detection of respiratory pathogens from animal specimens with minimal sample volume and reagent consumption [11]. These platforms can process dozens to hundreds of samples simultaneously, making them suitable for outbreak investigations, kennel surveillance, and large-scale epidemiological studies [1, 5, 11].

Detection of Novel and Unexpected Viruses

The ability of PCR panels to detect known pathogens is well established, but respiratory disease can also be caused by novel or emerging viruses. Next-generation sequencing (NGS) of nasal swab samples from dogs with respiratory signs has revealed the presence of novel taupapillomaviruses, the clinical significance of which remains to be fully elucidated [5, 9]. These findings suggest that a proportion of respiratory disease cases may be attributable to previously unrecognized viral agents. The integration of NGS with conventional PCR panels provides a comprehensive approach: panels detect known targets rapidly, while NGS can uncover unexpected or divergent sequences [5].

Furthermore, the emergence of SARS-CoV-2 as a pathogen of both dogs and cats underscores the importance of maintaining panels that can be rapidly adapted to include novel agents [3, 6]. Thieulent and colleagues developed a specific four-plex assay that incorporated SARS-CoV-2 alongside common CIRDC pathogens, demonstrating that panel expansion is both technically feasible and clinically relevant [6].

Clinical Interpretation and Asymptomatic Carriage

One of the central challenges in interpreting respiratory panel results is the phenomenon of asymptomatic carriage. Multiple pathogens included in respiratory panels, including B. bronchiseptica, M. cynos, and CPIV, can be detected in the respiratory tracts of healthy dogs without clinical signs of disease [12]. A study specifically designed to assess asymptomatic carriage found that a significant proportion of apparently healthy dogs tested positive for one or more CIRDC-associated pathogens [12]. This complicates the attribution of causality: a positive PCR result confirms the presence of pathogen nucleic acid but does not unequivocally prove that the detected agent is the cause of the observed clinical signs [1, 12].

The interpretation of positive results must therefore incorporate clinical context, including the severity and type of clinical signs, radiographic findings, and the presence of co-morbidities [2, 7]. Quantitative PCR (qPCR) may provide additional discriminatory power, as higher pathogen loads are generally more strongly associated with clinical disease [4]. However, thresholds distinguishing asymptomatic carriage from active infection have not been definitively established for all pathogens [4].

Risk Factors and Epidemiological Considerations

Several risk factors have been associated with the development of CIRDC in dogs, including age, vaccination status, housing density, and recent exposure to other dogs in environments such as shelters, boarding facilities, dog parks, and training classes [2, 7]. An observational study in Canadian small animal clinics identified that dogs in multi-dog households and those with a history of recent kenneling were at significantly increased risk [7]. Similarly, a more recent analysis found that inherent breed risk factors and environmental stressors contributed to disease expression [2].

Vaccination is a major confounder in respiratory panel interpretation. Modified live vaccines (MLV) for CPIV, CAV-2, and B. bronchiseptica can lead to positive PCR results for days to weeks after administration [13]. Ruch-Gallie and colleagues demonstrated that puppies vaccinated with MLV products frequently tested positive by PCR for the vaccine virus strains, and these positive results could persist for variable periods [13]. This finding is critical for clinical practice: a positive PCR result in a recently vaccinated animal does not necessarily indicate infection with a wild-type pathogen. Clinicians must therefore document vaccination history and consider the expected duration of vaccine virus shedding when interpreting results [13].

Diagnostic Workflow and Decision Tree

The diagnostic workflow for respiratory disease in dogs and cats typically begins with a thorough clinical examination, followed by sample collection. The most common sample types for respiratory PCR panels include conjunctival, nasal, or oropharyngeal swabs, as well as bronchoalveolar lavage fluid and tracheal washes [1, 11]. Deep nasal swabs are generally preferred for upper respiratory tract infections, while lower respiratory tract samples are indicated for pneumonia [5].

The decision to deploy a respiratory virus panel is guided by clinical severity, chronicity, and suspicion of a viral etiology. A representative diagnostic decision tree is illustrated below.

flowchart TD
    A[Patient presenting with respiratory signs], > B{Clinical signs acute or chronic?}
    B, Acute, > C[History of exposure? (kennel, shelter, multi-pet)]
    B, Chronic, > D[Previous diagnostic workup negative?]
    C, > E{Severity of signs?}
    E, Mild, > F[Supportive care, PCR panel if episodes persist]
    E, Severe, > G[Collect nasal swab / BAL]
    D, > G
    G, > H[Run multiplex respiratory virus panel]
    H, > I{Result interpretation}
    I, Positive for target, > J[Assess Ct value, vaccination history, clinical correlation]
    J, High viral load, not vaccinated, > K[Confirm pathogen; treat accordingly]
    J, Low viral load or vaccinated, > L[Consider asymptomatic carriage or vaccine shedding; treat if clinical signs match]
    I, Negative for all targets, > M[Consider NGS / virome analysis; evaluate for novel pathogens]
    M, > N[Consider non-infectious causes (allergy, neoplasia, foreign body)]

This decision tree emphasizes the integration of PCR results with clinical judgment. A negative panel result does not rule out an infectious etiology, as the causative agent may not be included in the panel or may be present at levels below the assay's limit of detection [5]. In such cases, advanced testing such as NGS may be indicated [5, 9].

Comparison with Other Diagnostic Modalities

Respiratory virus panels offer distinct advantages over traditional culture and serology. Viral isolation is labor-intensive, time-consuming, and often yields false-negative results for fastidious or unculturable viruses [1, 11]. Serology provides only indirect evidence of past exposure and cannot distinguish between active infection and previous vaccination or exposure [13]. In contrast, PCR detects pathogen nucleic acid directly from clinical specimens with high sensitivity and specificity, and results can be available within hours [4, 8].

However, PCR does not distinguish between viable and non-viable organisms, which is a limitation in the context of assessing treatment efficacy or contagiousness [1]. Quantitative PCR can partially address this by monitoring changes in cycle threshold (Ct) values over time, with a rising Ct (decreasing target concentration) suggestive of resolving infection [4].

Bioinformatics and Data Integration

The increasing throughput of respiratory panels, particularly when coupled with NGS, generates large datasets that require sophisticated bioinformatic analysis [5, 9]. Sequence data from NGS must be processed through pipelines that include quality control, host genome subtraction, taxonomic classification, and identification of known and novel viral sequences [5]. The use of public databases such as those maintained by the National Center for Biotechnology Information (NCBI) is central to these analyses.

For quantitative PCR panels, Ct values are logged into laboratory information management systems (LIMS) and can be used for monitoring pathogen prevalence trends over time [1]. Machine learning algorithms have been applied to integrative analyses combining Ct values, clinical metadata, and microbiome data to predict disease outcomes and identify optimal treatment protocols. The computational integration of these disparate data types is an area of active development in veterinary diagnostics.

Conclusions

Respiratory virus panels employing multiplex PCR technology are indispensable tools for the diagnosis and management of viral respiratory diseases in dogs and cats. These panels enable rapid, comprehensive detection of the major viral and bacterial agents associated with CIRDC and FURTD [1, 3, 4, 8]. However, their clinical interpretation requires careful consideration of factors including asymptomatic carriage [12], post-vaccinal shedding [13], and the possibility of novel or unsuspected pathogens [5, 9]. The integration of panels with NGS provides a powerful diagnostic framework capable of closing the diagnostic gap for cases where conventional panels are negative [5]. As the field progresses, continued validation of new targets, standardization of quantitative thresholds, and the development of computational tools for data integration will further enhance the clinical utility of respiratory virus panels.

References

[1] Snedden K, Frye E, Conklin R, et al. A retrospective analysis of canine, feline, and equine respiratory polymerase chain reaction panels performed at the New York State Animal Health Diagnostic Center (January-December 2023). J Am Vet Med Assoc. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40139158/

[2] Ouyang Z, Joffe D, Weese JS, et al. Risk factors for canine infectious respiratory disease complex and the pathogens associated with the disease. Can Vet J. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39494180/

[3] Michael HT, Waterhouse T, Estrada M, et al. Frequency of respiratory pathogens and SARS-CoV-2 in canine and feline samples submitted for respiratory testing in early 2020. J Small Anim Pract. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/33521974/

[4] Dong J, Tsui WNT, Leng X, et al. Validation of a real-time PCR panel for detection and quantification of nine pathogens commonly associated with canine infectious respiratory disease. MethodsX. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/38053622/

[5] Thieulent CJ, Laverack M, Carossino M, et al. Detection of pathogens in dogs with respiratory disease during winter 2023-2024 using multiplex qPCR/RT-qPCR assays and next-generation sequencing. Front Vet Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40905007/

[6] Thieulent CJ, Carossino M, Peak L, et al. Development and Validation of a Panel of One-Step Four-Plex qPCR/RT-qPCR Assays for Simultaneous Detection of SARS-CoV-2 and Other Pathogens Associated with Canine Infectious Respiratory Disease Complex. Viruses. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37766287/

[7] Joffe DJ, Lelewski R, Weese JS, et al. Factors associated with development of Canine Infectious Respiratory Disease Complex (CIRDC) in dogs in 5 Canadian small animal clinics. Can Vet J. 2016. URL: https://pubmed.ncbi.nlm.nih.gov/26740697/

[8] Dong J, Tsui WNT, Leng X, et al. Development of a three-panel multiplex real-time PCR assay for simultaneous detection of nine canine respiratory pathogens. J Microbiol Methods. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/35753509/

[9] Altan E, Seguin MA, Leutenegger CM, et al. Nasal virome of dogs with respiratory infection signs include novel taupapillomaviruses. Virus Genes. 2019. URL: https://pubmed.ncbi.nlm.nih.gov/30632017/

[10] Arnold HK, Hanselmann R, Duke SM, et al. Chronic clinical signs of upper respiratory tract disease associate with gut and respiratory microbiomes in a cohort of domestic felines. PLoS One. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/36454958/ *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[11] Goodman LB, Anderson RR, Slater M, et al. High-throughput Detection of Respiratory Pathogens in Animal Specimens by Nanoscale PCR. J Vis Exp. 2016. URL: https://pubmed.ncbi.nlm.nih.gov/27929456/

[12] Okonkowski LK, Szlosek D, Ottney J, et al. Asymptomatic carriage of canine infectious respiratory disease complex pathogens among healthy dogs. J Small Anim Pract. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/34060088/

[13] Ruch-Gallie R, Moroff S, Lappin MR. Adenovirus 2, Bordetella bronchiseptica, and Parainfluenza Molecular Diagnostic Assay Results in Puppies After vaccination with Modified Live Vaccines. J Vet Intern Med. 2016. URL: https://pubmed.ncbi.nlm.nih.gov/26692461/

[14] Piewbang C, Rungsipipat A, Poovorawan Y, et al. Development and application of multiplex PCR assays for detection of virus-induced respiratory disease complex in dogs. J Vet Med Sci. 2017. URL: https://pubmed.ncbi.nlm.nih.gov/27628592/